|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ERCC3 |
Gene summary for ERCC3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ERCC3 | Gene ID | 2071 |
| Gene name | ERCC excision repair 3, TFIIH core complex helicase subunit | |
| Gene Alias | BTF2 | |
| Cytomap | 2q14.3 | |
| Gene Type | protein-coding | GO ID | GO:0000278 | UniProtAcc | P19447 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2071 | ERCC3 | LZE4T | Human | Esophagus | ESCC | 7.12e-12 | 2.72e-01 | 0.0811 |
| 2071 | ERCC3 | LZE7T | Human | Esophagus | ESCC | 4.91e-04 | 4.91e-01 | 0.0667 |
| 2071 | ERCC3 | LZE8T | Human | Esophagus | ESCC | 4.84e-08 | 1.81e-01 | 0.067 |
| 2071 | ERCC3 | LZE20T | Human | Esophagus | ESCC | 1.37e-04 | 1.88e-01 | 0.0662 |
| 2071 | ERCC3 | LZE24T | Human | Esophagus | ESCC | 7.02e-20 | 4.61e-01 | 0.0596 |
| 2071 | ERCC3 | LZE21T | Human | Esophagus | ESCC | 4.86e-05 | 2.26e-01 | 0.0655 |
| 2071 | ERCC3 | LZE6T | Human | Esophagus | ESCC | 1.22e-02 | 1.47e-01 | 0.0845 |
| 2071 | ERCC3 | P1T-E | Human | Esophagus | ESCC | 8.89e-08 | 3.42e-01 | 0.0875 |
| 2071 | ERCC3 | P2T-E | Human | Esophagus | ESCC | 2.11e-27 | 3.98e-01 | 0.1177 |
| 2071 | ERCC3 | P4T-E | Human | Esophagus | ESCC | 7.11e-21 | 5.85e-01 | 0.1323 |
| 2071 | ERCC3 | P5T-E | Human | Esophagus | ESCC | 1.56e-12 | 2.03e-01 | 0.1327 |
| 2071 | ERCC3 | P8T-E | Human | Esophagus | ESCC | 4.40e-23 | 4.14e-01 | 0.0889 |
| 2071 | ERCC3 | P9T-E | Human | Esophagus | ESCC | 2.40e-15 | 2.41e-01 | 0.1131 |
| 2071 | ERCC3 | P10T-E | Human | Esophagus | ESCC | 2.26e-26 | 4.28e-01 | 0.116 |
| 2071 | ERCC3 | P11T-E | Human | Esophagus | ESCC | 5.41e-12 | 5.35e-01 | 0.1426 |
| 2071 | ERCC3 | P12T-E | Human | Esophagus | ESCC | 2.43e-40 | 7.26e-01 | 0.1122 |
| 2071 | ERCC3 | P15T-E | Human | Esophagus | ESCC | 5.34e-21 | 4.53e-01 | 0.1149 |
| 2071 | ERCC3 | P16T-E | Human | Esophagus | ESCC | 1.06e-27 | 4.60e-01 | 0.1153 |
| 2071 | ERCC3 | P17T-E | Human | Esophagus | ESCC | 6.73e-11 | 3.14e-01 | 0.1278 |
| 2071 | ERCC3 | P19T-E | Human | Esophagus | ESCC | 3.58e-11 | 5.75e-01 | 0.1662 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006979111 | Esophagus | ESCC | response to oxidative stress | 303/8552 | 446/18723 | 7.15e-22 | 1.30e-19 | 303 |
| GO:004477216 | Esophagus | ESCC | mitotic cell cycle phase transition | 281/8552 | 424/18723 | 4.63e-18 | 4.45e-16 | 281 |
| GO:000734615 | Esophagus | ESCC | regulation of mitotic cell cycle | 293/8552 | 457/18723 | 8.00e-16 | 5.64e-14 | 293 |
| GO:000941113 | Esophagus | ESCC | response to UV | 115/8552 | 149/18723 | 3.29e-15 | 1.93e-13 | 115 |
| GO:000635414 | Esophagus | ESCC | DNA-templated transcription, elongation | 76/8552 | 91/18723 | 8.35e-14 | 4.11e-12 | 76 |
| GO:190198713 | Esophagus | ESCC | regulation of cell cycle phase transition | 242/8552 | 390/18723 | 3.86e-11 | 1.26e-09 | 242 |
| GO:000931419 | Esophagus | ESCC | response to radiation | 277/8552 | 456/18723 | 4.42e-11 | 1.43e-09 | 277 |
| GO:0070482111 | Esophagus | ESCC | response to oxygen levels | 218/8552 | 347/18723 | 6.91e-11 | 2.17e-09 | 218 |
| GO:190199013 | Esophagus | ESCC | regulation of mitotic cell cycle phase transition | 191/8552 | 299/18723 | 1.35e-10 | 3.94e-09 | 191 |
| GO:0036293111 | Esophagus | ESCC | response to decreased oxygen levels | 201/8552 | 322/18723 | 8.37e-10 | 2.04e-08 | 201 |
| GO:000636814 | Esophagus | ESCC | transcription elongation from RNA polymerase II promoter | 56/8552 | 69/18723 | 1.40e-09 | 3.30e-08 | 56 |
| GO:0001666111 | Esophagus | ESCC | response to hypoxia | 192/8552 | 307/18723 | 1.59e-09 | 3.69e-08 | 192 |
| GO:00903053 | Esophagus | ESCC | nucleic acid phosphodiester bond hydrolysis | 163/8552 | 261/18723 | 3.07e-08 | 5.73e-07 | 163 |
| GO:000854410 | Esophagus | ESCC | epidermis development | 193/8552 | 324/18723 | 2.87e-07 | 4.19e-06 | 193 |
| GO:00063673 | Esophagus | ESCC | transcription initiation from RNA polymerase II promoter | 56/8552 | 77/18723 | 1.30e-06 | 1.59e-05 | 56 |
| GO:000635211 | Esophagus | ESCC | DNA-templated transcription, initiation | 86/8552 | 130/18723 | 1.88e-06 | 2.19e-05 | 86 |
| GO:00063602 | Esophagus | ESCC | transcription by RNA polymerase I | 42/8552 | 55/18723 | 3.41e-06 | 3.78e-05 | 42 |
| GO:003239214 | Esophagus | ESCC | DNA geometric change | 62/8552 | 90/18723 | 7.02e-06 | 7.04e-05 | 62 |
| GO:003250813 | Esophagus | ESCC | DNA duplex unwinding | 58/8552 | 84/18723 | 1.23e-05 | 1.14e-04 | 58 |
| GO:000991310 | Esophagus | ESCC | epidermal cell differentiation | 122/8552 | 202/18723 | 1.69e-05 | 1.51e-04 | 122 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0342022 | Esophagus | ESCC | Nucleotide excision repair | 54/4205 | 63/8465 | 2.01e-09 | 2.17e-08 | 1.11e-08 | 54 |
| hsa030222 | Esophagus | ESCC | Basal transcription factors | 35/4205 | 45/8465 | 1.01e-04 | 4.06e-04 | 2.08e-04 | 35 |
| hsa0342032 | Esophagus | ESCC | Nucleotide excision repair | 54/4205 | 63/8465 | 2.01e-09 | 2.17e-08 | 1.11e-08 | 54 |
| hsa0302211 | Esophagus | ESCC | Basal transcription factors | 35/4205 | 45/8465 | 1.01e-04 | 4.06e-04 | 2.08e-04 | 35 |
| hsa034202 | Liver | HCC | Nucleotide excision repair | 41/4020 | 63/8465 | 3.59e-03 | 1.12e-02 | 6.22e-03 | 41 |
| hsa034203 | Liver | HCC | Nucleotide excision repair | 41/4020 | 63/8465 | 3.59e-03 | 1.12e-02 | 6.22e-03 | 41 |
| hsa034204 | Oral cavity | OSCC | Nucleotide excision repair | 49/3704 | 63/8465 | 3.48e-08 | 2.91e-07 | 1.48e-07 | 49 |
| hsa03022 | Oral cavity | OSCC | Basal transcription factors | 28/3704 | 45/8465 | 9.53e-03 | 2.11e-02 | 1.08e-02 | 28 |
| hsa0342011 | Oral cavity | OSCC | Nucleotide excision repair | 49/3704 | 63/8465 | 3.48e-08 | 2.91e-07 | 1.48e-07 | 49 |
| hsa030221 | Oral cavity | OSCC | Basal transcription factors | 28/3704 | 45/8465 | 9.53e-03 | 2.11e-02 | 1.08e-02 | 28 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ERCC3 | SNV | Missense_Mutation | novel | c.1666G>A | p.Asp556Asn | p.D556N | P19447 | protein_coding | deleterious(0) | probably_damaging(0.913) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| ERCC3 | SNV | Missense_Mutation | c.203N>C | p.Lys68Thr | p.K68T | P19447 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-A8-A079-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD | |
| ERCC3 | SNV | Missense_Mutation | novel | c.1361T>G | p.Val454Gly | p.V454G | P19447 | protein_coding | deleterious(0) | possibly_damaging(0.888) | TCGA-A8-A0A6-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | epirubicin | CR |
| ERCC3 | SNV | Missense_Mutation | novel | c.374N>T | p.Ala125Val | p.A125V | P19447 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AR-A5QP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| ERCC3 | SNV | Missense_Mutation | rs764062606 | c.1079N>A | p.Arg360His | p.R360H | P19447 | protein_coding | tolerated(0.06) | benign(0.333) | TCGA-C8-A8HP-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
| ERCC3 | SNV | Missense_Mutation | rs746827111 | c.974G>A | p.Arg325Gln | p.R325Q | P19447 | protein_coding | deleterious(0.03) | benign(0.34) | TCGA-E2-A14P-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Targeted Molecular therapy | trastuzumab | SD |
| ERCC3 | SNV | Missense_Mutation | novel | c.394N>A | p.Gln132Lys | p.Q132K | P19447 | protein_coding | tolerated(0.17) | benign(0.038) | TCGA-S3-AA11-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | letrozole | CR |
| ERCC3 | insertion | Frame_Shift_Ins | novel | c.135_136insCCCTACC | p.Val46ProfsTer5 | p.V46Pfs*5 | P19447 | protein_coding | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | |||
| ERCC3 | SNV | Missense_Mutation | rs773390535 | c.412G>A | p.Glu138Lys | p.E138K | P19447 | protein_coding | tolerated(0.27) | benign(0.107) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ERCC3 | SNV | Missense_Mutation | rs563550613 | c.2105N>T | p.Ala702Val | p.A702V | P19447 | protein_coding | tolerated(0.65) | benign(0.003) | TCGA-EA-A4BA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 2071 | ERCC3 | TRANSCRIPTION FACTOR, KINASE, CLINICALLY ACTIONABLE, DNA REPAIR, ENZYME | Platinum compounds | 25069034 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |